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http://www.molecular-cancer.com/content/13/1/4RESEARCH Open AccessGPCR-like signaling mediated by smoothened
contributes to acquired chemoresistance
through activating Gli
Xia Zhan, Juan Wang, Yuan Liu, Yuanqiu Peng and Wenfu Tan*Abstract
Background: Smoothened (Smo), which possesses a structural similarity with classic G-protein coupled receptors
(GPCR), is the most important molecular target in Hedgehog (Hh) signaling system for developing anticancer drugs;
however, whether Smo may transmit GPCR-like signaling to activate the canonical transcriptional factor Gli of Hh
signaling system and consequently to be involved in the Gli-dependent biological events remains controversial.
Results: In this study, using the acquired chemoresistant cancer cell lines and their respective parental cells, we
found that Smo may activate Gli through Gαi, Gβγ-JNK signaling axis, thereby promoting the Gli-dependent
acquired chemoresistance. These observations were further complementarily strengthened by data obtained from
chemosensitive cancer cells with artificially elevated Hh pathway activity.
Conclusions: Hence, our data demonstrate that GPCR-like signaling mediated by Smo contributes to the acquired
chemoresistance through activating the canonical Hh transcriptional factor Gli; therefore improving our knowledge
of the nature of the signal transduction of Smo and the molecular mechanisms responsible for the acquired
chemoresistance maintained by Hh pathway. Moreover, our data that JNK after activated by Smo-Gβγ signaling axis
may stimulate the Gli activity and consequently promotes acquired chemoresistance expose a promising and
potential target for developing anti-cancer drugs aimed at Hh pathway and for combating the acquired resistance
raised by using of anti-cancer drugs targeting Smo.
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The Hedgehog (Hh) signaling pathway plays critical
roles for embryonic development and postnatal tissue
homeostasis in organisms ranging from insects to mam-
mals [1]. The activation Hh pathway is initiated by bind-
ing of the secreted Hh proteins, including Sonic, Indian
and Desert Hedgehog (SHh, IHh and DHh, respectively)
to the 12-transmembrane receptor Patched (Ptch), there-
by liberating the Ptch-mediated inhibitory effect on
Smoothened (Smo), a 7-pass transmembrane protein
and a key component in the Hh signaling pathway. This
subsequently causes the accumulation of Smo in the pri-
mary cilium and a series of consequent intracellular
events, finally resulting in the activation of the canonical
transcriptional factor Gli which consists of Gli1, Gli2* Correspondence: wftan@fudan.edu.cn
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stated.and Gli3 [2]. Analogous to other pathways active during
embryonic development, inappropriate Hh pathway ac-
tivity has been demonstrated to be critical for the initi-
ation and progression of various kinds of tumors.
Aberrant Hh pathway activity for tumors may occur ei-
ther by mutations in key components of Hh pathway or
by the production of Hh ligands in tumor cells in an au-
tonomous and non-autonomous manner [3].
Given that the addiction of many types of tumors to
aberrant Hh pathway activity, a variety of antagonists
targeting Hh pathway have been developed for the treat-
ment of cancers. Among them, the majority function as
inhibitors of Hh pathway by targeting Smo, a critical
component for canonical Hh pathway [4]. In this regard,
dissecting the characteristics of signal transduction elic-
ited from Smo is crucial and an area of intense investiga-
tion, as it may help us with the development of
antagonists targeting Smo and its downstream effectors.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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sic G-protein coupled receptors (GPCR), has long been
suggested to couple with heterotrimeric G proteins
[5-7]. Indeed, it has been shown that Smo may interact
with Gαi and subsequently acitivate the transcriptional
activity of Gli (Ci in drosophila cells) in Drosophila Cl8
cells, Sf9 cells, and NIH3T3 cells, indicating the require-
ment of Gαi for the activation of Gli mediated by Smo
[8,9]. However, this argument is challenged by the obser-
vations that pertussis toxin (PTX), which may ADP-
ribosylate and consequently uncouple Gi from GPCR,
fails to impact the Gli-dependent biological events such
as chick neural tube patterning and some patterning
events in zebrafish embryonic development [5,10]. On
the other hand, after coupled to Gαi, Smo may exert a
variety of biological activities independently of Gli, such
as migration of murine embryonic fibroblasts, tubulo-
genesis of endothelial cells, and calcium spike activity of
embryonic spinal cells [11-13]. Moreover, recent study
indicate that Smo may contribute to the survival of dif-
fuse large B-cell lymphoma cells by coupling to Gαi and
Gα12 and subsequently activate NF-κB independently of
Gli [14]. These studies suggest that the association be-
tween heterotrimeric Gαi proteins and Smo remains far
from being fully understood, especially in the context of
cancer biology. Meanwhile, in the case of canonical sig-
nal transduction of GPCR, ligand binding causes con-
formational changes in the structure of GPCRs, endowing
them with abilities to function as a guanine nucleotide ex-
change factor (GEF). The exchange of GDP for GTP at
the Gα subunit induces its dissociation from Gβγ dimmer
[15]. To our knowledge, whether and how Gβγ, after dis-
sociated from Gα subunit, may impact the Smo dependent
Gli activity remains as well unclear.
Although great achievements have been made for the
molecular-targeted anti-cancer drugs, traditional chemo-
therapy is still one of the most efficient approaches for
treatments of cancers. Many studies have shown that Hh
signaling pathway activity plays critical roles in main-
taining the chemoresistant phenotype of acquired che-
moresistant cancer cells [16-23]. In this study, utilizing
well established acquired chemoresistant cancer cell
lines and their respective parental ones, we provide a
series of complementary evidences to show that Smo
may promote acquired chemoresistance by activating Gli
through Gαi and Gβγ−JNK signaling axis, therefore re-
vealing that GPCR-like signaling elicited from Smo is in-
volved in the canonical Hedgehog-Gli signaling pathway
activation and the acquired chemoresistance.
Materials and methods
Drugs
Doxorubicin (Dox), Vincristine (VCR), Etoposide (VP16),
Imatinib were purchased from Sigma-Aldrich (St. Louis,MO). The Hedgehog pathway antagonists cyclopamine
(cyc), Robotnikinin (Robo) and GANT58 were obtained
from Biovision (Milpitas, CA). The Gi antagonist Pertussis
Toxin (PTX) was obtained from Invitrogen (Grand Island,
NY). The JNK pathway antagonist TAT-TI-JIP was ob-
tained from Calbiochem (Darmstadt, Germany). The
agonist of Hh pathway SAG was obtained from Selleck
Chemicals (Houston, TX).Cell culture
The K562 human chronic myelogenous leukemia cell
line, KB human epidermoid carcinoma cell line, NIH-
3 T3 mouse embryo fibroblast cells, and HEK293T hu-
man epithelial kidney cells were purchased from the
American Type Culture Collection and cultured accord-
ing to the manufacturer’s instructions. The Dox selected
multidrug tolerant K562/A02 subline was obtained from
the Institute of Hematology, Chinese Academy of Med-
ical Sciences (Tianjin, China), which was routinely main-
tained in medium containing 200 ng/ml of Dox [24].
The VCR selected multidrug tolerant KB/VCR subline
was obtained from Zhongshan University of Medical Sci-
ences (Guangzhou, China) and was routinely maintained
in medium containing 200 ng/ml of VCR [25]. Both re-
sistant cells were authenticated by comparing their fold
resistance with that of the parental cells and examining
the expression levels of ABC transporters. All experi-
ments using K562/A02, and KB/VCR cells were per-
formed with cells growing in the absence of Dox or VCR
for at least 5–7 days to avoid drug associated secondary
effects.Plasmid constructions and lentivirus
8 × Gli-binding site luciferase reporter (8 × GBS-lucifer-
ase) and 8 ×mutant Gli-binding site luciferase reporter
(8 × GBS-luciferase mutant) plasmids were kindly pro-
vided by Dr. Hiroshi Sasaki. pRL-Renilla luciferase plas-
mid was purchased from Promega (Madison, WI). The
mutant mouse plasmids SmoA1 (W539L) was generated
from pEGFP-mSmo (a kind gift from Dr. Philip Beachy)
using QuikChange Site-Directed Mutagenesis kit from
Agilent (Santa Clara, CA) and confirmed by sequenc-
ing. The SmoA1 was next engineered into pLVX-EGFP-
3FLAG-Puro lentivector. The pCDNA3 Flag MKK7-JNK1,
pCDNA3 Flag JNK1(APF) and pCDNA3 Flag MKK7-JNK1
(APF) plasmids were purchased from Addgene (Cambridge,
MA) and confirmed by sequencing. These three plasmids
were engineered into pLVX-EGFP-3FLAG-Puro lentivector.
The PIRES2-ZsGreen1-Gβ1, PIRES2-ZsGreen1-Gγ2, and
PIRES2-ZsGreen1-Gα transducin plasmids were purchased
from Yrbio (Changsha, China) and were confirmed by se-
quencing. The Gα transducin (Gαt) plasmid was engi-
neered into pLVX-EGFP-3FLAG-Puro lentivector.
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tamine 2000 reagent (Invitrogen, Grand Island, NY) ac-
cording to the manufacturer’s instructions. The viral
stocks were prepared and infections were performed ac-
cording to previously reported [26].
Cell viability assay
The MTT assay was conducted as previously described
to determine the sensitivity of cells to chemotherapeutic
drugs [27].
Reverse transcription PCR (RT-PCR) and quantitative RT-
PCR (QT-PCR)
Total RNA was extracted from cells by RNAiso Plus Kit
from TaKaRa (Dalian, China) as the instructions pro-
vided by the manufacturer and processed directly to
cDNA by reverse transcription using SuperScript III kit
(TaKaRa). Semi-quantitative PCR amplification was car-
ried out using Stratagene mx3005p (Agilent Technolo-
gies). The quantitative PCR reactions were performed in
triplicate with the SYBR-Green kit (TaKaRa) in iCycler
iQ system (Bio-Rad; Hercules, CA). After reaction, the
PCR products were subjected to electrophoresis to en-
sure the amplification from mRNA but not contami-
nated genomic DNA. The mRNA levels of interested
genes were normalized to that of TATA. Primers for the










Cells were lysed in lysis buffer (50 mM Tris, pH 7.4,
150 mM NaCl, 1% NP-40, 1 mM sodium vanadate,
1 mM PMSF, 1 mM DTT, 10 mg/ml of leupeptin and
aprotinin) and subjected to immunoblot analysis. Pri-
mary antibodies against JNK, c-Jun, p-JNK, p-c-Jun, HA
(Cell Signaling Technology; Beverly, MA), Flag, GAPDH
(Santa Cruz Biotechnology; Santa Cruz, CA) were used
for immunoblot analysis as standard procedure.
Dual-luciferase reporter assay
Cells were seeded into 48-well plates. Twenty-four hours
later, cells were cotransfected with luciferase expression
constructs as indicated and Renilla luciferase using Lipo-
fectamine 2000 (Invitrogen). Luciferase activities present
in cellular lysates after indicated treatments were mea-
sured using a Dual-Luciferase reporter assay system from
Promega (Madison, WI) according to the manufactu-rer’s instructions and a luminometer (Molecular Device;
Sunnyvale, CA). The firefly luciferase values were normal-
ized to Renilla values.
Statistical analysis
Statistical differences were analyzed by the two-tailed
Student’s t test and P < 0.05 was considered as signifi-
cant. Asterisks denote statistical significance (*P < 0.05;
**P < 0.01; and ***P < 0.001).
Results
Acquired chemoresistant cancer cells exhibit aberrant
cell-autonomous Hh pathway activity
The requirement of Hh pathway activity for maintaining
the acquired chemoresistance indicates that acquired
chemoresistant cancer cells may harbor aberrant Hh
pathway activity via cell autonomous manner [3]. Elabor-
ate verification of this argument is a prerequisite for dis-
secting the nature of the signal transduction from Smo
to Gli in acquired chemoresistant cancer cells. In this re-
gard, we first examined the expressions of ligands of Hh
pathway in acquired chemoresistant cancer cells com-
pared to their respective parental ones. Using two well
established acquired chemoresistant cancer cells K562/
A02, KB/VCR and their respective parental cells human
chronic myelogenous leukemia cell line K562, human
epidermoid carcinoma cell line KB, we found that the
abundance of Hh ligands SHh, IHh and DHh were all
obviously elevated when compared to their respective
parental cancer cells as revealed by QT-PCR analysis
(Figure 1A), suggesting the possibility of cell-autono-
mous Hh pathway activity harbored by acquired che-
moresistant cancer cells. Next, we set out to evaluate
whether the elevated production of Hh ligands correlates
with the aberrant Hh pathway activity in acquired che-
moresistant cancer cells using Gli-luciferase assay to rule
out the non-cell autonomous Gli activation [3]. We ob-
served that the chemoresistant cancer cells harbored ab-
errant Hh pathway activity relative to respective parental
cells (Figure 1B). Meanwhile, treatment of acquired che-
moresistant cancer cells with Robo and cyc, specific
small molecular inhibitors targeting SHh and Smo, re-
spectively [28,29], caused significant reductions of the
aberrant Hh pathway activity in acquired chemoresistant
cancer cells K562/A02 and KB/VCR, whereas both Robo
and cyc did not affect Hh pathway activity in respective
chemosensitive cells (Figure 1B). Moreover, tomatidine,
a steriodal alkaloid structurally similar to cyc and lacking
activity against Hh pathway [30], exhibited no effect on
the Hh pathway activity in both chemoresistant and re-
spective chemosensitive cancer cells (Figure 1B). These
observations derived from Gli-luciferase reporter assay
were faithfully recapitulated by QT-PCR analysis of the
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Figure 1 Acquired chemoresistant cancer cells exhibit aberrant cell-autonomous Hh pathway activity. Representative data from three
independent experiments are expressed as mean ± s.d. A, Expressions of Hh pathway ligands SHh, IHh and DHh in acquired chemoresistant
cancer cells K562/A02 and KB/VCR compared to their respective parental cancer cells K562 and KB respectively by QT-PCR analysis. B, Gli
luciferase reporter activity in chemoresistant K562/A02 and KB/VCR cancer cells and their respective parental cancer cells K562 and KB determined
by luciferase reporter assay. The cells (4 × 104) seeded into 48-well plates were transfected with Gli luciferase reporter and pRL-Renilla luciferase
plasmids. After transfectinos for 24 h, the cells (around 100% confluency of adherent cells) in culture medium with 10% serum were further
treated with tomatidine (10 μM), Robo (10 μM) and cyc (3 μM) for 24 h. C, Expressions of the Hh pathway target genes Gli1 in acquired
chemoresistant K562/A02 and KB/VCR cancer cells and their respective parental cancer cells K562 and KB. The cells (2 × 105) were seeded into
6-well plates. After 24 h, the cells (around 100% confluency of adherent cells) in normal culture conditions were treated with tomatidine (10 μM),
Robo (10 μM) and cyc (3 μM) for 24 h were collected for examined by QT-PCR analysis. D, Treatment with the Robo circumvents the
chemoresistance of K562/A02 cells and KB/VCR cells to Dox and VCR respectively. K562/A02 cells and KB/VCR cells were seeded into 96-well
plates and incubated with Dox or VCR supplemented with or without various concentrations of Robo for 72 h.
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sidering that the chemoresistant cancer cells harbor aber-
rant cell-autonomous Hh pathway activity, it is conceivable
that interference Hh pathway by targeting its ligands may
sensitize acquired chemoresistant cancer cells to chemo-
therapy. Indeed, we found that exposure of chemoresistant
cancer cells K562/A02, KB/VCR to Robo resulted in ob-
viously sensitizing them to Dox and VCR, respectively
(Figure 1D), while Robo treatment failed to impact the sen-
sitivity of K562 and KB cells to Dox and VCR (data notshown). Hence, these data together clearly demonstrate that
chemoresistant cancer cells harbor cell-autonomous Hh
pathway activity.
Gαi and Gβγ are involved in mediating the Hh pathway
activity in chemoresistant cancer cells
Having established that acquired chemoresistant cancer
cells harbor cell-autonomous Hh pathway activation and
represent ideal models for dissecting the signal transduc-
tion nature of Hh pathway, we then asked whether and
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quently promote chemoresistance by activating Gli.
Considering that Smo may couple to Gαi in Drosophila
Cl8 cells, Sf9 cells, and NIH3T3 cells [8,9], we first set
out to examine whether interference with Gαi may re-
press the Gli activity in chemoresistant cancer cells. Ex-
posure of chemoresistant cancer cells to PTX, which
may uncouple Gαi from receptor activation by ADP
ribosylating Gαi [31], obviously suppressed the tran-
scriptional activity of Gli in K562/A02 cells and KB/
VCR cells as revealed by Gli-luciferase reporter assay
(Figure 2A), indicating the involvement of Gαi in the Gli
activation mediated by Smo in chemoresistant cancer
cells. We next investigated the contribution of Gβγ to
the activation of Gli in chemoresistant cancer cells by
ectopic expression of Gαt, which may quench Gβγ upon
dissociated from Gαi, thereby blocking the function
of Gβγ [32]. As expected, ectopic expression of Gαt in
K562/A02 cells and KB/VCR cells obviously suppressed
the Gli-luciferase reporter activity (Figure 2B), thus indi-
cating the participation of Gβγ in Gli activation. To fur-
ther provide direct evidences for the argument that both
Gαi and Gβγ are involved in mediating the signal from
Smo to Gli, we asked whether intervention of Gαi and
Gβγ may inhibit the Gli activation in response to SAG,
a specific small molecular agonist of Smo [33]. SAG
exposure provoked abundant Gli-luciferase reporter
activity in KB/VCR cells ((Figure 2C,D), whereas PTX
(Figure 2C) and Gαt (Figure 2D) obviously reduced
the Gli-luciferase activity in response to SAG. These
observations obtained by using KB/VCR cells were
well recapitulated in NIH-3 T3 cells exposed to SAG
(Figure 2E-F). Moreover, we observed that transfec-
tion of Gβ1 and Gγ2 plasmids into NIH-3 T3 cells
remarkably stimulated the Gli-lucidferase reporter
activity (Figure 2G); further demonstrating that Gαi
and Gβγ upon dissociated from Gαi may transmit the
signal from Smo to Gli. Taking these results together,
we can conclude that Smo may couple to Gαi and
both Gαi and Gβγ are involved in activating Gli me-
diated by Smo in chemoresistant cancer cells.
Next, we examined whether interference with Gαi and
Gβγ may circumvent the chemoresistance of acquired
chemoresistant cancer cells. We found that treatment of
KB/VCR cells (Figure 2H) with PTX or ectopic expres-
sion of Gαt into K562/A02 cells (Figure 2I) by lenti-
virus approach resulted in remarkably sensitizing the
KB/VCR cells and K562/A02 cells to chemotherapeutic
drugs VCR and Dox, respectively. Moreover, these rever-
sals of acquired chemoresistance elicited by PTX and
Gαt were accompanied by the repressions of Hh path-
way activity in KB/VCR cells and K562/A02 cells as
reflected by the reductions of transcript levels of Gli1
(Figure 2J-K). Meanwhile, we observed that treatment ofK562 and KB cells with PTX or transfection of Gαt did
not increase the sensitivity of K562 and KB cells to
chemotherapy (data not shown). Therefore, these data
further demonstrate that Gαi and Gβγ are required for
Smo-mediated Gli activation and consequently for Gli-
dependent chemoresistance in acquired chemoresistant
cancer cells.
Gαi and Gβγ are required for the chemoresistance
promoted by reconstituted Hh pathway activity in KB cells
We next set out to provide complementary evidences
for the notion that Smo may couple to Gαi and both
Gαi and Gβγ may be involved in the Gli-dependent ac-
quired chemorsistance mediated by Smo in chemoresis-
tant cancer cells. Taking advantage of the lenti-virus
approach, we constitutively activated the Hh pathway ac-
tivity in chemosensitive cancer cells KB by ectopic ex-
pression of a Flag-tagged mouse mutant plasmid Smo
(W539L, SmoA1), a frequent mutation in Smo which
causes constitutive activation of Hh pathway in medullo-
blastoma cancers [34]. Ectopic expression of Flag-tagged
SmoA1 in KB cells (Figure 3A) caused the KB cells in-
sensitive to VCR treatment (Figure 3B), and concomitant
activation of the Hh pathway activity in KB cells as jud-
ged by the increased expression of Gli1 at mRNA level
(Figure 3C). Of interest, PTX treatment or expression of
HA-tagged Gαt by lenti-virus approach (Figure 3A) re-
stored the sensitivity of KB cells with forced expression of
SmoA1 to VCR (Figure 3B,D), paralleling the reductions of
expression of Gli1 at mRNA level (Figure 3C,E). Thus,
these results together further strengthen that Gαi is
coupled to Smo and both Gαi and Gβγ are involved in the
Gli activation mediated by Smo and subsequently in main-
taining the chemoresistance phenotype.
Gβγ may promote Gli activity through JNK in
chemoresistant cancer cells
JNK is a well known downstream effector of Gβγ [35].
We then asked whether Gβγ, when released from Gαi
after Smo activation, may activate Gli via JNK. To this
end, we first tested whether inhibition of the Hh path-
way may repress JNK activation in chemoresistant
cancer cells. Exposure of K562/A02 cells with Robo
(Figure 4A) or treatment of K562/A02 cells and KB/
VCR cells with cyc (Figure 4B) led to reductions of the
phosphorylation of JNK, indicating that Hh signaling
may activate JNK in chemoresistant cancer cells. This
was further supported by the observation that SHh sig-
nificantly provoked JNK activation in 293 T cells, reach-
ing a maximum at 10 min (Figure 4C). Next, we set out
to determine the requirement of JNK activation for Gli
activity in chemoresistant cancer cells. Inhibition of JNK
in K562/A02 cells by JIP (Figure 4D), a peptide inhibitor
specifically targeting JNK [36,37], or by transfection
K
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Figure 2 Gαi and Gβγ are involved in mediating the Hh pathway activity in chemoresistant cancer cells. The data are expressed as the
means ± s.d. from three independent experiments. A, Cells as indicated were transiently transfected with Gli luciferase reporter and pRL-Renilla
luciferase plasmids, followed by treatment with PTX (100 ng/ml) for 24 h. The data are expressed as fold induction relative to K562 cells. B, Cells
as indicated were transiently transfected with Gli luciferase reporter and pRL-Renilla luciferase plasmids together with GFP or Gαt. The cells were
harvested for dual luciferase reporter assay after transfection for 48 h. C, KB/VCR cells after transfected with Gli luciferase reporter and pRL-Renilla
luciferase plasmids were treated with SAG (100 ng/ml) with or without PTX (100 ng/ml) in culture medium with 0.5% serum for 24 h. D, KB/VCR
cells after transfected with Gli luciferase reporter and pRL-Renilla luciferase plasmids supplemented with GFP or Gαt were stimulated with SAG in
culture medium with 0.5% serum for 24 h. E, NIH-3T3 cells were transfected with Gli luciferase reporter and pRL-Renilla luciferase plasmids, and
were treated with SAG (100 ng/ml) with or without PTX (100 ng/ml) in culture medium with 0.5% serum for 24 h. F, NIH-3T3 cells after
transfected with Gli luciferase reporter and pRL-Renilla luciferase plasmids supplemented with GFP or Gαt were stimulated with SAG in culture
medium with 0.5% serum for 24 h and were collected for dual lucifearse assay. G, NIH-3T3 cells were transfected with Gli luciferase reporter and
pRL-Renilla luciferase plasmids supplemented with GFP, and Gβ1 together with Gγ2 respectively. H-I, Interference with the functions of Gαi and
Gβγ by treatment with PTX (H) and transfection with Gαt (I) increases the sensitivity of KB/VCR (H) and K562/A02 (I) to chemotherapeutic drugs.
J-K, Interference with the functions of Gαi and Gβγ by treatment with PTX (J) and transfection with Gαt (K) reduces the Gli1 expressions at mRNA
level in KB/VCR cells and K562/A02 cells.
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(APF), a plasmid of dominant negative mutant of JNK
[38], abundantly impaired the Gli activity in chemoresis-
tant cancer cells as judged by Gli-luciferase reporter
assay, therefore suggesting that JNK is required for
maintaining the cell-autonomous Gli activation in ac-
quired chemoresistant cancer cells. This argument was
further confirmed by the results that JIP obviously abol-
ished the Gli activity provoked by SAG in KB/VCR cells
(Figure 4F). Together, these findings suggest that JNK isinvolved in the cell-autonomous Gli activation in che-
moresistant cancer cells.
We next set out to examine whether Gβγ may activate
Gli though JNK in acquired chemoresistant cancer cells.
We observed that treatment of chemoresistant cancer
cells K562/A02 (Figure 5A) and KB/VCR (Figure 5B)
with PTX or with transfection of Gαt resulted in de-
creasing the phosphorylation of JNK. Furthermore, PTX
and Gαt remarkably abolished the phosphorylation of


























































































































































Figure 3 Gαi and Gβγ are involved in the chemoresistance of KB cells with forced expression of SmoA1 by activating Gli. KB cells were
infected with lenti-virus harboring GFP, Flag-tagged SmoA1, and Flag-tagged SmoA1 plus Gαt with a HA tag. A, Western blot analysis of p-JNK,
Flag tagged SmoA1 and HA tagged Gαt. B, SmoA1 causes KB cells insensitive to VCR, while PTX (100 ng/ml) treatment recovers the sensitivity of
KB cells with forced expression of SmoA1 to VCR. Data are expressed as average ± s.d. from three separate experiments. C, SmoA1 enhances the
expression of Gli1 at mRNA level, while PTX treatment for 24 h abolishes this enhancement of Gli1 expression at mRNA level. The results are
expressed as the means ± s.d. from three to four independent experiments. D, SmoA1 causes KB cells insensitive to VCR, while co-expression of
Gαt with SmoA1 by lenti-virus approach circumvents this tolerance to VCR. Data are expressed as average ± s.d. from three separate experiments.
E, SmoA1 increases the expression of Gli1 at mRNA level in KB cells compared to GFP cohort, while co-expression of Gαt with SmoA1 reduces the
expression of Gli1. The results are expressed as the means ± s.d. from three to four independent experiments.
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that Gβγ may mediate Gli activation elicited by Smo
through JNK. This argument was further strengthened
by the observation that JIP significantly inhibited the
Gli-luciferase reporter activity provoked by transfection of
Gβ1 and Gγ2 subunits into NIH-3T3 cells (Figure 5E).
Collectively, our findings demonstrate that after released
from Gαi, Gβγ may activate Gli via JNK in chemoresistant
cancer cells.
JNK activity is required for maintaining the
chemoresistance maintained by Hh pathway
Having established that Gβγ may transduce the signaling
from Smo to Gli via activating JNK in chemoresistant
cancer cells, we next tested the biological relevance of
Gli activation mediated by JNK to chemoresistance using
acquired chemoresistant cancer cells. We saw that inter-
ference of JNK function with JIP or with forced expres-
sion of JNK dominant negative mutant JNK1a1 (APF) bylenti-virus approach significantly sensitized the K562/
A02 cells to Dox (Figure 6A,C), concomitantly accom-
panying the reductions of the expressions of Gli1 at
mRNA level (Figure 6B,D). Given that JNK may promote
chemoresistance through activating Gli, it is conceivable
that artificial activation of JNK in chemosensitive cancer
cells may result in Gli activation and subsequently che-
moresistance. Indeed, taking advantage of the MKK7 and
JNK1 fusion plasmid (MKK7-JNK1) engineered into a
lenti-virus vector, which may activate JNK activity [39], we
observed that artificial JNK activation rendered chemosen-
sitive cancer cells K562 tolerant to Dox (Figure 6E), simul-
taneously increasing the Gli activity as reflected by
QT-PCR analysis of the Gli1 expression (Figure 6F); while
the negative control MKK7-JNK1(APF) for MKK7-JNK1
did not impact either the sensitivity of K562 cells to Dox
(Figure 6E) or the expression of Gli1 at mRNA level
(Figure 6F). Interestingly, GANT58, a small molecular an-

























































































































Figure 4 JNK is involved in transmitting the signal from Hh to Gli in acquired chemoresistant cancer cells. Values of the blots (p-JNK)
relative to GAPDH quantified by Image J are statistical different (data not shown). A-B, Treatment with Hh inhibitors Robo (A) and cyc (B)
suppresses the phosphorylation of JNK in acquired chemoresistant cancer cells. Blots are representative data from at least three independent
experiments. C, Exposure of NIH-3 T3 cells to SHh causes phosphorylation of JNK. 293 T cells were treated with SHh (100 ng/ml) for different times
as indicated, and were harvested for western blot analysis. GAPDH were used as a loading control. Blots are representative results from at least
three separate experiments. D, K562/A02 cells and its parental K562 cells were transfected with Gli luciferase reporter and pRL-Renilla
luciferase plasmids, and were treated with peptide JNK inhibitor JIP for 24 h. Data are mean ± s.d. from three separate experiments. E, Acquired
chemoresistant cancer cells K562/A02, KB/VCR and their respective parental cells K562 and KB were transfected with Gli luciferase reporter and
pRL-Renilla luciferase plasmids with GFP or Gαt. Data are mean ± s.d. from three separate experiments. F, KV/VCR cells were transfected with Gli
luciferase reporter and pRL-Renilla luciferase plasmids, and were treated with SAG with or without JIP for 36 h. Data are mean ± s.d. from three
separate experiments.
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http://www.molecular-cancer.com/content/13/1/4vity of K562 cells with ectopic expression of MKK7-JNK1
to Dox (Figure 6E). Taken together, these results com-
plementarily demonstrate that JNK may activate Gli in
chemoresistant cancer cells, thereby maintaining the che-
moresistance phenotype.
We next investigated whether the JNK activation is re-
quired for the chemoresistance promoted by ectopic ex-
pression of SmoA1. To this end, we artificially activated
the Hh pathway activity using SmoA1 in K562 cells by
lenti-virus approaches, like did in KB cells. Ectopic ex-
pression of SmoA1 in K562 cells resulted in obvious
phosphorylations of JNK and its canonical downstream ef-
fector c-Jun, whereas JNK dominant negative mutant
JNK1(APF) diminished these phosphorylations (Figure 7A),
confirming the inhibitory effect of JNK1(APF) on the
function of JNK. Similar to the observations obtained in
KB cells, SmoA1 caused chemoresistance of K562 cells to
Dox (Figure 7B), VP16 (Figure 7C) and BCR-ABL tyrosine
kinase inhibitors Imatinib (Figure 7D), simultaneously ac-
companying increased Hh pathway activity as reflected byenhancement of Gli1 mRNA expression (Figure 7E).
Moreover, JNK1 (APF) restored the sensitivity of the K562
cells with artificial elevated Hh pathway to Dox, VP16 and
Imatinib (Figure 7C-D), concomitantly reducing the ex-
pression of Gli1 provoked by SmoA1 (Figure 7E). Collect-
ively, our findings further confirm that JNK is involved in
the chemoresistance mediated by Hh pathway and that
after dissociation from Gαi initiated by Smo activation,
Gβγ may stimulate the Gli activity through JNK and sub-
sequently promote chemoresistance.
Discussion
Hh signaling pathway has been shown to be critical for a
variety of physiological and pathological conditions, such
as embryonic patterning, maintenance of postnatal tissue
homeostasis, as well as initiation and progression of can-
cers [41], whereas the molecular mechanisms respon-
sible for its signaling transduction remain to be fully
understood. Because of the structural homology with


























































Figure 5 Gβγ may transmit the signal from Smo to Gli via JNK. Values of the blots (p-JNK) relative to JNK quantified by Image J are statistical
different (data not shown). A-B, K562/A02 (A) and KB/VCR cells (B) were treated with PTX (100 ng/ml) or transfected with Gαt plasmids, and cells
were harvested for western blot analysis. K562 and KB cells were used as negative control. Blots are representative results from at least three
separate experiments. C, K562/A02 cells were pre-treated with PTX (100 ng/ml) for 1 h followed by exposure to SAG (100 nM) for 10 mins. Blots
are representative results from at least three experiments. D, K562/A02 cells were transfected with GFP or Gαt plasmids, and were stimulated with
SAG (100 nM) for 10 mins. The immunoblots are representative of three separate experiments with identical results. E, NIH-3 T3 cells transfected
with Gli luciferase reporter and pRL-Renilla luciferase plasmids plus GFP or Gβ1γ2 plasmids were treated with JIP for 36 h, and were collected for
dual luciferase reporter assay. The results are represented as fold induction relative to GFP cohort, and were represented as mean ± s.d. from three
separate experiments.
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http://www.molecular-cancer.com/content/13/1/4ability to couple with heterotrimeric G proteins Gαi
[5-7]. However, the contribution of Gαi to the Hh signal-
ing transduction is quite controversial and unclear, espe-
cially in the cancer biology. Information available so far
suggests that it is context-dependent and cell-type
dependent for the ability of Smo coupling to Gαi and for
the subsequent participation of Gli in the biological sig-
nificance initiated by the interaction of Smo and Gαi
[42,43]. In the present study, we provide complementary
evidences to show that both Gαi and Gβγ are required
for the Hh pathway activity and the subsequent acquired
chemoresistance by activating its canonical transcrip-
tional factor Gli, confirming the ability of Smo coupling
to Gαi and the requirement of Gαi for the Gli-
dependent biological significance in the context of ac-
quired chemoresistance. Moreover, we found that Gβγ,
after released from Gαi, are also be involved in the Gli
activation and acquired chemoresistance through acti-
vating JNK. Indeed, by artificially increasing the Hh
pathway activity in chemosensitive cancer cells, we de-
termined that both Gαi and Gβγ-JNk signaling axis are
required for the Gli activity and Gli-dependent acquired
chemoresistance mediated by SmoA1. Our data thatGPCR-like signaling mediated by Smo contributes to the
acquired chemoresistance by activating Gli improve our
interpretations of the underlying mechanisms for the ac-
quired chemoresistance promoted by Hh pathway and
help us with improving the chemotherapeutic efficiency
by using Hh inhibitors [44]. Meanwhile, this study shed
light on the understanding the nature of signaling trans-
duction of Smo in cancer biology.
Deregulated Hh signaling has been implicated in a
wide range of cancers, such as medulloblastoma, basal
cell carcinoma, glioblastoma, leukemia, breast cancer,
pancreatic cancer, prostate cancer, lung caner, colon can-
cer, to name a few [45]. Aberrant Hh pathway activity
may result from gain-of-function and loss-of-function
mutations in key components in Hh pathway, such as
PTCH, Smo, and Sufu [3]. Hh pathway may as well be
activated in tumors by overexpression of Hh ligands
functioning in a cell-autonomous or non-cell autono-
mous manner. However, the activation of Hh pathway in
tumor cells via a cell-autonomous manner is challenged
by many controversial observations and remains to be
fully elucidated [3], for example, the inability of muta-
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Figure 6 JNK is involved in maintaining the chemoresistance of acquired chemoresistant cancer cells by activating Gli. The data are
expressed as the means ± s.d. from three independent experiments. A, Treatment with the peptide JNK inhibitor JIP circumvents the
chemoresistance of K562/A02 cells to Dox. K562/A02 cells were seeded into 96-well plates, and incubated with vehicle control or Dox
supplemented with or without JIP (2 μM) for 72 h. B, K562/A02 cells were treated with JIP (2 μM) for 24 h, and were collected for QT-PCR analysis
of the expression of Gli1. C, Ectopic expression of JNK dominant negative mutant plasmid JNK1(APF) by lenti-virus approach enhances the
sensitivity of K562/A02 cells to Dox. K562/A02 cells with stable expressions of JNK1(APF) and GFP were seeded into 96-well plates, and incubated
with vehicle control or Dox for 72 h. D, K562/A02 cells with stable expressions of JNK1(APF) and GFP were collected for QT-PCR analysis of
expression of Gli1. E, Activation of JNK in K562 cells by JNK constitutive mutant plasmid MKK7-JNK1 causes insensitivity of K562 cells to Dox, while
inhibition of Gli activity by GANT58 recovers the sensitivity of K562 cells to Dox. K562 cells with forced expression of MKK7-JNK1, MKK7-JNK1(APF),
GFP by lenti-virus approach were seeded in 96-well plates, and incubated with vehicle control or Dox supplemented with or without various
GANT58 (10 μM) for 72 h. F, K562 cells with forced expression of MKK7-JNK1, MKK7-JNK1(APF), GFP by lenti-virus approach were harvested for
QT-PCR analysis of Gli1 expressions.
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http://www.molecular-cancer.com/content/13/1/4to initiate pancreatic cancer [46]. In this study, we used
the well established acquired chemoresistant cancer cell
lines as an experimental model system for investigating
the contribution of heterotrimeric G proteins and their
downstream effectors to Gli activation mediated by Smo.
Our data clearly demonstrate that acquired chemoresis-
tant cancer cells harbor aberrant Hh pathway activity in
a cell-autonomous manner, thus increasing our know-
ledge about the mechanisms behind Hh activation in can-
cers. On the other hand, many studies have shown the
loss of Hh pathway activity in cancer cells possessing ele-
vated Hh pathway activity after cultured in vitro [47-49],
arguing against the use of in vitro cultured cancer cell
lines for many kinds of investigations related to Hh path-
way in cancer biology, ranging from dissecting molecular
mechanisms underlying Hh signaling transduction to pre-
clinical evaluation of Hh inhibitors. In this regard, our datathat acquired chemoresistant cancer cells harbor aberrant
Hh pathway activity in a cell-autonomous manner identify
acquired chemoresistant cancer cell lines as potential and
useful in vitro experimental model systems for investiga-
tions related to Hh pathway in cancer biology.
How does the Smo-coupled Gαi signaling link the
transcriptional factor Gli in chemoresistant cancer cells?
In the case of classical GPCR signaling transduction, the
exchange of GDP for GTP at Gαi subunit results in the
activation of Gαi, thereby repressing the adenyl cyclase
and subsequently decreasing the conversion of ATP to
cAMP. Reduced cAMP level implies downregulation of
the activity of PKA [15]. Considering that PKA is the
key determinant for proteasome proteolysis of Gli by
phophorylating it at multiple sites [50,51], we can envi-
sion that Gαi after activated by Smo signaling may pro-
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Figure 7 JNK is involved in maintaining the chemoresistance of K562 cells with forced expression of SmoA1 by activating Gli. A, K562
cells with forced expression of GFP, SmoA1 or SmoA1 plus JNK1(APF) by lenti-virus approach were collected for immunoblotting of phosphorylation of
JNK and c-Jun. GAPDH were used as a loading control. B-D, Ectopic expression of SmoA1 causes K562 cells resistant to anti-cancer drugs Dox (B),
VP-16 (C), and Imatinib (D), while JNK dominant negative mutant JNK1(APF) abolishes these resistances. K562 cells with forced expressions of GFP,
SmoA1 or SmoA1 plus JNK1(APF) by lenti-virus approach were seeded in 96 well plates, and were incubated with or without Dox, VP-16, and Imatinib
for 72 h. Data are shown as mean ± s.d. from three separated experiments. E, K562 cells with forced expressions of GFP, SmoA1 or SmoA1 plus JNK1
(APF) by lenti-virus approach were harvested for QT-PCR analysis of the expression of Gli1 at mRNA level.
Zhan et al. Molecular Cancer 2014, 13:4 Page 11 of 13
http://www.molecular-cancer.com/content/13/1/4activity of PKA in chemoresistant cancer cells in despite
of required further verifications. On the other hand, in
the case of classic GPCR signaling transduction, the Gβγ
dimmer after releasing from Gαi may stimulate a couple
of downstream effectors, such as PKC, PI3K and JNK
[35]. Data from other labs indicate that dissociated Gβγ
dimmer initiated by Smo signaling may potentially pro-
mote the activation of Gli via PKC and PI3K in che-
moresistant cancer cells [52-55]. However, in the present
study, we provide complementary evidences showing
that Smo may as well promote the activation of Gli via
Gβγ-JNK signaling axis. Hence, our data together with
that from other labs suggest that Smo utilizes the G pro-
tein signaling to its full potential for activating the tran-
scriptional factor Gli.JNK, a key member of the family of MAPKs, is also
called stress activated protein kinase (SAPK) and can be
activated by environmental and genototoxic stress and
other extracellular stimulus [56]. JNK activation has also
been linked to acquired chemoresistance by promotion
of chemoresistance or by reversal of chemoresistance,
relying on the duration and strength of the signaling
[56,57]. Here, we show that JNK may function as a
downstream effector of Gβγ for transmitting the signal-
ing from Smo to Gli, thereby promoting the Gli-
dependent acquired chemoresitance. Thus, this finding
will help us with better understanding the role of JNK in
acquired chemoresistance. Similar to ERK1/2, another
critical member of MAPKs, JNK signaling is as well
deregulated in many types of cancers [56,58]. However,
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plex and far from being fully elucidated, in other words,
exhibiting context-specific and cell type-specific manner.
JNK has been well known to confer the positive impact on
proliferation and survival of cancer cells via its target AP1,
a transcriptional factor composing Jun and Fos [59]. Of
interest, data in our study imply that Gli represents a puta-
tive downstream target of JNK, thus facilitating our better
interpretation of the molecular mechanisms responsible
for promoting the development of cancers by JNK. Al-
though inhibitors of membrane protein Smo have been
approved for treatment of basal cell carcinoma, the early
acquired resistance to such inhibitors proposes the need
for additional downstream targets [60]. Hence, our data
imply JNK as a new target for the treatment of the tumors
with acquired resistance to Smo inhibitors. In this regard,
how JNK promotes the activation of Gli is quite interest-
ing, and is currently being investigated in our lab.
Conclusions
In this study, we demonstrate that GPCR-like signaling
mediated by Smo contributes to the acquired chemore-
sistance through activating the canonical Hh transcrip-
tional factor Gli. Our data improve our knowledge of the
nature of the signal transduction of Smo and the mo-
lecular mechanisms responsible for the acquired che-
moresistance maintained by Hh pathway. Moreover, the
findings that JNK after activated by Smo-Gβγ signaling
axis may stimulate the Gli activity and consequently pro-
mote acquired chemoresistance expose a promising and
potential target for developing anti-cancer drugs aimed
at Hh pathway and for combating the acquired resist-
ance raised by using of anti-cancer drugs targeting Smo.
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